Acorda Therapeutics Inc., of Ardsley, N.Y., reported the fourth quarter 2016 net sales of Ampyra (dalfampridine) extended-release tablets, 10 mg were $132 million. Full-year net sales amounted to $493 million, an increase of approximately 13 percent over the 2015 net sales.